Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02243241 · ClinicalTrials.gov registry record · Phase 1
The Effect of Hydrocodone Bitartrate (HYD) Extended-Release Tablets on QT /QTc Intervals in Healthy Adult Subjects
A Phase 1 study, sponsored by Purdue Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 208
- Enrollment target
NCT02243241: Completed Phase 1 study, sponsored by Purdue Pharma.
NCT02243241 is a Phase 1 study that has completed, run by Purdue Pharma. The registered enrollment target is 208 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (247% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02243241, a Phase 1 study, has completed, sponsored by Purdue Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 208 participants
- Enrollment target
Study Summary
Evaluate the effect of multiple doses (once daily for 3 days each of HYD 80, 120, and 160 mg tablets) on the QT/QTc interval.
Primary Outcome
The electrocardiogram (ECG) effects of HYD 80 mg (day 9) on the QT/QTc interval
Interventions
- DRUG Moxifloxacin
- DRUG Placebo for moxifloxacin
- DRUG HYD
- DRUG Placebo for HYD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2012-11 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
What the finished NCT02243241 record still lists
NCT02243241 is an interventional study that assigns participants to a tested intervention. The registered 208 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (247% higher).
The record links to 0 conditions, and to 4 interventions - of which Moxifloxacin is the first listed.
NCT02243241 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02243241 about?
NCT02243241 is a clinical study titled "The Effect of Hydrocodone Bitartrate (HYD) Extended-Release Tablets on QT /QTc Intervals in Healthy Adult Subjects". Evaluate the effect of multiple doses (once daily for 3 days each of HYD 80, 120, and 160 mg tablets) on the QT/QTc interval.
What is the current status of trial NCT02243241?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 208 participants. The study started on 2012-11. Estimated completion is 2013-05.
What interventions are being tested in trial NCT02243241?
The interventions under investigation include: Moxifloxacin (DRUG), Placebo for moxifloxacin (DRUG), HYD (DRUG), Placebo for HYD (DRUG).
Who is sponsoring clinical trial NCT02243241?
This trial is sponsored by Purdue Pharma, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02243241's enrollment target sits among peer trials
208 250th of 2000 higher than 1,749 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465774 · 208 participants
Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions
- NCT03803332 · 208 participants · NA
A Trial Comparing Interpersonal Therapy to Exposure Therapy for PTSD Due to Military Sexual Trauma (MST) in Male and Female Military Personnel
- NCT04732065 · 208 participants · Phase 1
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
- NCT05293756 · 208 participants · NA
OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia